U.S. markets open in 1 hour 41 minutes
  • S&P Futures

    4,204.25
    +10.00 (+0.24%)
     
  • Dow Futures

    34,535.00
    +93.00 (+0.27%)
     
  • Nasdaq Futures

    13,637.25
    +39.50 (+0.29%)
     
  • Russell 2000 Futures

    2,250.10
    +10.20 (+0.46%)
     
  • Crude Oil

    64.57
    -0.14 (-0.22%)
     
  • Gold

    1,820.00
    +4.30 (+0.24%)
     
  • Silver

    27.42
    -0.05 (-0.17%)
     
  • EUR/USD

    1.2076
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.5610
    0.0000 (0.00%)
     
  • Vix

    18.30
    -0.85 (-4.44%)
     
  • GBP/USD

    1.3904
    +0.0011 (+0.08%)
     
  • USD/JPY

    109.1660
    +0.0810 (+0.07%)
     
  • BTC-USD

    56,635.53
    -1,415.39 (-2.44%)
     
  • CMC Crypto 200

    1,477.19
    +5.78 (+0.39%)
     
  • FTSE 100

    7,118.93
    +42.76 (+0.60%)
     
  • Nikkei 225

    29,357.82
    +26.45 (+0.09%)
     

Novavax Allows Participants On Placebo Arm To Get COVID-19 Vaccine In Trials

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Novavax Inc (NASDAQ: NVAX) said that participants in its ongoing COVID-19 vaccine trials in South Africa and the U.K. could receive additional shots, ensuring those who received a placebo can also get the active vaccine.

  • Allowing volunteers to crossover to the active vaccine will enable participants to continue in trials and remain blinded.

  • The company said it planned to cross over participants in its ongoing large, late-stage study in the U.S. and Mexico. The company plans to read out initial clinical data during the second quarter.

  • As part of the updated trial protocol, all participants in the U.K. and the U.S. will be offered the chance to receive an additional round of shots, the company said.

  • Participants who opt to do so will receive two additional doses of either vaccine for those who initially received placebo or placebo for those who first got the vaccine.

  • Price Action: NVAX shares are trading 4.2% lower at $178 in the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.